PART I . Overview We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001725160-26-000014 | EDGAR | 86K words |
| 2025-03-26 | 2024-12-31 | 0001725160-25-000067 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001725160-24-000080 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001725160-23-000048 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001725160-22-000053 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001725160-21-000075 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001725160-25-000161 | EDGAR | 58K words |
| 2025-08-06 | 2025-06-30 | 0001725160-25-000149 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001725160-25-000105 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001725160-24-000173 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001725160-24-000158 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001725160-24-000107 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001725160-23-000196 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001725160-23-000155 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001725160-23-000113 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001725160-22-000200 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001725160-22-000155 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001725160-22-000093 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001725160-26-000010 | EDGAR | 3K words |
| 2026-01-09 | 0001725160-26-000003 | EDGAR | — |
| 2025-12-15 | 0001725160-25-000164 | EDGAR | — |
| 2025-11-10 | 0001725160-25-000159 | EDGAR | — |
| 2025-08-26 | 0001725160-25-000154 | EDGAR | — |
| 2025-08-06 | 0001725160-25-000147 | EDGAR | — |
| 2025-06-18 | 0001725160-25-000127 | EDGAR | — |
| 2025-06-02 | 0001725160-25-000119 | EDGAR | — |
| 2025-05-20 | 0001725160-25-000108 | EDGAR | — |
| 2025-05-14 | 0001725160-25-000104 | EDGAR | — |
124 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001725160 |
| Ticker | ZNTL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.zentalis.com |
| Listed | 2020-04-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report